Adaptive Biotechnologies (ADPT)
(Delayed Data from NSDQ)
$3.72 USD
-0.18 (-4.62%)
Updated May 16, 2024 04:00 PM ET
After-Market: $3.73 +0.01 (0.27%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Price, Consensus and EPS Surprise
ADPT 3.72 -0.18(-4.62%)
Will ADPT be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ADPT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ADPT
Compared to Estimates, Adaptive Biotechnologies (ADPT) Q1 Earnings: A Look at Key Metrics
Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Misses Revenue Estimates
ADPT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Exploring Analyst Estimates for Adaptive Biotechnologies (ADPT) Q4 Earnings, Beyond Revenue and EPS
Adaptive Biotechnologies (ADPT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Prothena (PRTA) Soars 18.7%: Is Further Upside Left in the Stock?
Other News for ADPT
Aristotle Capital Focus Growth Q1 2024 Commentary
Aristotle Capital Large Cap Growth Q1 2024 Commentary
Aristotle Capital Core Equity Q1 2024 Commentary
Piper Sandler Sticks to Their Buy Rating for Adaptive Biotechnologies (ADPT)
Analysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI), Warby Parker (WRBY) and Adaptive Biotechnologies (ADPT)